Table 1.
Patients' Baseline Demographic and Clinical Characteristics
| Patient demographics | Overall patients (N = 844) | Patients receiving immunotherapy (N = 528) | Patients receiving targeted therapy (N = 316) | P valuea |
|---|---|---|---|---|
| Age, yrs, mean (SD) | 74.72 (13.7) | 74.69 (13.5) | 74.78 (14.0) | .051 |
| Age-group, yrs, N (%) | <.01 | |||
| 65–74 | 441 (52.3) | 286 (54.2) | 155 (49.1) | |
| 75–84 | 285 (33.8) | 186 (35.2) | 99 (31.3) | |
| 85+ | 118 (14.0) | 56 (10.6) | 62 (19.6) | |
| Male, N (%) | 547 (64.8) | 352 (66.7) | 195 (61.7) | .041 |
| Race, N (%) | .991 | |||
| White | 801 (94.9) | 500 (94.7) | 301 (95.3) | |
| Asian | 8 (0.9) | 4 (0.8) | 4 (1.3) | |
| Black | 21 (2.5) | 16 (3.0) | 5 (1.6) | |
| Hispanic | 6 (0.7) | 3 (0.6) | 3 (0.9) | |
| Other | 8 (0.9) | 5 (0.9) | 3 (0.9) | |
| Year of index treatment, N (%) | .025 | |||
| 2011 | 85 (10.1) | 28 (5.3) | 57 (18.0) | |
| 2012 | 275 (32.6) | 193 (36.6) | 82 (25.9) | |
| 2013 | 203 (24.1) | 132 (25.0) | 71 (22.5) | |
| 2014 | 281 (33.3) | 175 (33.1) | 106 (33.5) | |
| Charlson Comorbidity Index, mean (SD) | 8.39 (2.22) | 8.39 (2.23) | 8.40 (2.20) | .58 |
| Baseline cancer therapy, N (%) | ||||
| Excision surgery | 448 (53.1) | 275 (52.1) | 173 (54.7) | .24 |
| Chemotherapy or biologic therapy | 398 (47.2) | 243 (46.0) | 155 (49.1) | .02 |
| Interferon alpha | 28 (3.3) | 13 (2.5) | 15 (4.7) | .04 |
| Baseline hospitalization, N (%) | 253 (30.0) | 151 (28.6) | 102 (32.3) | .01 |
| Baseline emergency department visit, N (%) | 257 (30.5) | 153 (29.0) | 104 (32.9) | .01 |
| Baseline comorbidities, N (%) | ||||
| Anxiety | 81 (9.6) | 63 (11.9) | 18 (5.7) | <.01 |
| Cardiovascular disease | 396 (46.9) | 254 (48.1) | 142 (44.9) | .42 |
| Cerebrovascular disease | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Chronic obstructive pulmonary disease | 62 (7.3) | 39 (7.4) | 23 (7.3) | .75 |
| Diabetes | 126 (14.9) | 83 (15.7) | 43 (13.6) | <.01 |
| Depression | 51 (6.0) | 35 (6.6) | 16 (5.1) | <.01 |
a
For binary and categorical variables, the between-group differences were assessed using χ2 tests. For continuous variables, the between-group differences were assessed using the Wilcoxon rank-sum test. P <5% was considered statistically significant.
SD indicates standard deviation.